Increased Production of Functional Recombinant Human Clotting Factor IX by Baby Hamster Kidney Cells Engineered to Overexpress VKORC1, the Vitamin K 2,3-Epoxide-reducing Enzyme of the Vitamin K Cycle-Reference-Cited by-同舟云学术

Increased Production of Functional Recombinant Human Clotting Factor IX by Baby Hamster Kidney Cells Engineered to Overexpress VKORC1, the Vitamin K 2,3-Epoxide-reducing Enzyme of the Vitamin K Cycle

Published:2005-09 Issue:36 Volume:280 Page:31603-31607
ISSN:0021-9258
Container-title:Journal of Biological Chemistry
language:en
Short-container-title:Journal of Biological Chemistry

Author:

Wajih Nadeem,Hutson Susan M.,Owen John,Wallin Reidar

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference22 articles.

1. Recombinant factor VIIa (NovoSeven®) as a hemostatic agent

2. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates

3. Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis

4. Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases

5. Warfarin and the Vitamin K-Dependent γ-Carboxylation System

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanism of VKORC1 and VKORC1L1 signaling in the effects of sodium dehydroacetate on coagulation factors in rat hepatocytes;Toxicology in Vitro;2023-03

2. A genome-wide CRISPR-Cas9 knockout screen identifies FSP1 as the warfarin-resistant vitamin K reductase;Nature Communications;2023-02-14

3. Effect of prepropeptide replacement on γ-carboxylation and activity of recombinant coagulation factor IX;Biotechnology Letters;2022-06-22

4. Recent advances in the production of recombinant factor IX: bioprocessing and cell engineering;Critical Reviews in Biotechnology;2022-04-17

5. Calumenin knockdown, by intronic artificial microRNA, to improve expression efficiency of the recombinant human coagulation factor IX;Biotechnology Letters;2022-04-12